Thrivent Financial for Lutherans Sells 1,051 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Thrivent Financial for Lutherans trimmed its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 4.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,603 shares of the biopharmaceutical company’s stock after selling 1,051 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Agios Pharmaceuticals were worth $1,061,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in Agios Pharmaceuticals by 13.0% in the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock valued at $7,824,000 after acquiring an additional 30,764 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in Agios Pharmaceuticals by 79.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after buying an additional 231,164 shares in the last quarter. Caxton Associates LP acquired a new stake in Agios Pharmaceuticals in the first quarter valued at approximately $1,087,000. Vanguard Group Inc. boosted its position in Agios Pharmaceuticals by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock valued at $123,096,000 after buying an additional 59,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after buying an additional 388,381 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $60.00 to $56.00 in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $52.50.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $41.33 on Friday. Agios Pharmaceuticals, Inc. has a 52-week low of $19.80 and a 52-week high of $53.28. The company has a 50-day simple moving average of $45.04 and a two-hundred day simple moving average of $40.11. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -6.54 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. During the same period in the previous year, the company posted ($1.51) earnings per share. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. On average, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.